Entero Therapeutics, Inc.
General ticker "ENTO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.0M (TTM average)
Entero Therapeutics, Inc. follows the US Stock Market performance with the rate: 37.1%.
Estimated limits based on current volatility of 4.3%: low 2.30$, high 2.51$
Factors to consider:
- Total employees count: 11 as of 2016
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.08$, 6.65$]
- 2024-12-30 to 2025-12-30 estimated range: [0.40$, 2.50$]
Financial Metrics affecting the ENTO estimates:
- Negative: with PPE of -0.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -304.14 <= 0.33
- Negative: Inventory ratio change, % of 100 > 0.84
- Negative: negative Industry operating cash flow (median)
- Negative: 0.01 < Interest expense per share per price, % of 0.55
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: 41.86 < Shareholder equity ratio, % of 52.34 <= 63.39
Short-term ENTO quotes
Long-term ENTO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM |
| Operating Expenses | $12.68MM | $15.77MM |
| Operating Income | $-12.68MM | $-15.77MM |
| Non-Operating Income | $-1.95MM | $-0.02MM |
| Interest Expense | $0.02MM | $0.02MM |
| R&D Expense | $0.69MM | $5.03MM |
| Income(Loss) | $-14.63MM | $-15.79MM |
| Profit(Loss)* | $-14.63MM | $-15.79MM |
| Stockholders Equity | $2.74MM | $3.60MM |
| Assets | $5.44MM | $6.88MM |
| Operating Cash Flow | $-22.34MM | $-12.38MM |
| Capital expenditure | $0.00MM | $0.50MM |
| Investing Cash Flow | $0.00MM | $-0.50MM |
| Financing Cash Flow | $15.74MM | $15.23MM |
| Earnings Per Share** | $-407.37 | $-46.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.